​GOPALGANJ SCIENCE & TECHENOLOGY​

​UNIVERSITY, GOPALGANJ-8105​

​Assignment On Importance Of​

​Inorganic Pharmacy II​

​Course Code: PHR151​

​Course Tittle: Inorganic Pharmacy-II​

​Submitted By​ ​Submitted To​

​ tudent ID: 24PHR022​

S
​Session: 2024-25​ ​ hadija Akter​
K
​Year: 1​​st​ ​Assistant Professor​
​Semester: 2​​nd​
​Department Of Pharmacy, GSTU​
​Department of Pharmacy, GSTU.​

​1​​|​​Page​
 ​Date of submission: 12-07-26​

​INDEX​
​Course Tittle: Inorganic Pharmacy- II​

​Course Code:PHR151​

​Chapter: Impurities in Medicinal substance​

​List​ ​Topic Name​

​1​ ​Introduction​

​2​ ​Medicinal Substances​

​3​ ​Definition and Classification of Impurities​

​4​ ​Sources of Impurities​

​5​ ​Principles of Impurity Analysis​

​6​ ​Qualitative Analysis of Impurities​

​7​ ​Quantitative Analysis of Impurities​

​8​ ​Tests of Purity​

​9​ ​Modern Analytical Techniques Used in Impurity Analysis​

​10​ ​Conclusion and References​

​2​​|​​Page​
 ​▪​ ​Introduction​​:​
​ he pharmaceutical industry plays a vital role in protecting human health by​
T
​developing and manufacturing safe, effective, and high-quality medicinal​
​products. The therapeutic efficacy and safety of a medicine depend not only​
​on the pharmacological activity of its active pharmaceutical ingredient (API)​
​but also on its purity. Even a highly effective drug may become unsafe or​
​ineffective if it contains impurities beyond the permissible limits. Therefore,​
​impurity control is a fundamental aspect of pharmaceutical chemistry and​
​quality assurance.​

​ edicinal substances are rarely obtained in a completely pure state. During​

M
​their synthesis, purification, formulation, storage, transportation, and​
​packaging, various unwanted substances may be introduced into the final​
​product. These unwanted substances are known as impurities. While some​
​impurities may be harmless in trace amounts, others can reduce drug stability,​
​decrease therapeutic efficacy, interfere with analytical procedures, or produce​
​toxic effects. Consequently, the identification, control, and minimization of​
​impurities are essential to ensure the quality and safety of pharmaceutical​
​products.​

​ he significance of impurity analysis has increased considerably with the​

T
​advancement of pharmaceutical science and the implementation of stringent​
​regulatory requirements. Modern analytical methods enable the detection and​
​quantification of impurities at very low concentrations, ensuring that​
​medicinal substances comply with internationally accepted quality standards.​

​ he study of impurities includes understanding their sources, classification,​

T
​methods of detection, quantitative determination, and tests of purity. This​
​knowledge helps pharmaceutical scientists develop safer and more stable​
​medicines while ensuring compliance with regulatory standards. Thus,​
​impurity analysis forms a fundamental component of inorganic​
​pharmaceutical chemistry and plays a crucial role in maintaining the quality,​
​safety, and efficacy of medicinal substances throughout their shelf life.​

​▪​ ​Medicinal Substances :​

​ edicinal substances, also known as pharmaceutical substances or drug​
M
​substances, are chemical compounds used in the diagnosis, prevention,​
​treatment, mitigation, or cure of diseases. They may consist of inorganic​

​3​​|​​Page​
 c​ ompounds, organic compounds, biological molecules, or naturally derived​
​substances. Before a medicinal substance can be formulated into tablets,​
​capsules, injections, ointments, or other dosage forms, it must satisfy​
​stringent standards of identity, strength, purity, and quality.​

​ he quality of a medicinal substance depends on several critical factors,​

T
​including its chemical composition, physical characteristics, stability, and​
​absence of harmful contaminants. Pharmaceutical manufacturers invest​
​considerable resources in maintaining these quality attributes because even​
​minor variations can influence therapeutic performance. Consequently,​
​quality control laboratories continuously monitor medicinal substances using​
​standardized analytical procedures prescribed by official pharmacopoeias.​

​ edicinal substances may be produced through chemical synthesis,​

M
​extraction from natural sources, fermentation, or biotechnological methods.​
​Regardless of their origin, all pharmaceutical substances are susceptible to​
​contamination by various impurities during manufacturing and storage.​
​Therefore, impurity control forms an integral component of pharmaceutical​
​quality assurance.​

​▪​ ​Definition of Impurities :​

​ n impurity is any component in a medicinal substance that is not the active pharmaceutical​
A
​ingredient (API) or an approved excipient. These substances, which include synthetic​
​by-products, degradation products, residual solvents, reagents, and catalysts, are inherent to​
​the manufacturing process. Because absolute elimination is technically impossible, regulatory​
​bodies like the ICH establish specific safety limits for these contaminants. Modern analytical​
​methods are utilized to detect and quantify these impurities at trace levels, often measured in​
​parts per million or billion, ensuring that their presence remains within safe, non-toxic​
​thresholds for patient safety and product stability.​

​▪​ ​Classification of Impurities:​

​4​​|​​Page​
 I​ mpurities present in medicinal substances are broadly classified according to their chemical​
​origin and method of formation. Understanding this classification is essential because​
​different categories require different analytical methods and regulatory approaches.​

​⮚​ ​Organic Impurities :​

​ rganic impurities originate mainly during the synthesis and degradation of​
O
​pharmaceutical substances. They include unreacted starting materials, reaction​
​intermediates, by-products, degradation products, reagents, and ligand residues.​
​Organic impurities are often structurally related to the active pharmaceutical ingredient​
​and may influence both efficacy and toxicity.​

​ ecause of their structural similarity to the parent compound, organic impurities are​
B
​often the most difficult to separate and identify. Advanced chromatographic and​
​spectroscopic techniques are generally required for their analysis.​

​⮚​​Inorganic Impurities :​
I​ norganic impurities arise from manufacturing processes, catalysts, reagents, filter aids,​
​inorganic salts, heavy metals, corrosion products from equipment, and contaminated​
​water supplies. Examples include chloride, sulfate, nitrate, phosphate, calcium,​
​magnesium, iron, lead, arsenic, mercury, and cadmium.​

​ nlike organic impurities, inorganic contaminants usually do not possess​

U
​pharmacological activity but may exhibit toxic effects when present above acceptable​
​limits.​

​⮚​ ​Residual Solvents :​

​ esidual solvents are volatile organic chemicals used during pharmaceutical​
R
​manufacturing but not intended to remain in the finished product. Examples include​
​methanol, ethanol, acetone, benzene, toluene, chloroform, and hexane.​

​ he acceptable limits of residual solvents are determined according to their toxicity​

T
​and are strictly regulated under ICH guidelines.​

​⮚​​Microbial Impurities :​
​ icrobial contamination includes bacteria, fungi, yeast, viruses, endotoxins, and other​
M
​microorganisms introduced during manufacturing or storage. Such contamination is​
​particularly significant in sterile pharmaceutical preparations, biological products, and​
​injectable formulations.​

​⮚​​Elemental Impurities :​

​5​​|​​Page​
 ​ lemental impurities consist primarily of toxic metals that may originate from​
E
​catalysts, raw materials, manufacturing equipment, or environmental contamination.​
​Common elemental impurities include lead, arsenic, mercury, cadmium, nickel, cobalt,​
​and vanadium. These contaminants require highly sensitive instrumental methods for​
​accurate determination because even trace concentrations may produce significant​
​toxicological effects.​

​⮚​​Degradation Products :​
​ egradation products are impurities formed after the manufacture of the​
D
​pharmaceutical substance due to chemical instability. Factors such as heat, moisture,​
​oxygen, light, and inappropriate storage conditions accelerate degradation. Hydrolysis,​
​oxidation, reduction, decarboxylation, and photolysis are among the most common​
​degradation reactions encountered in pharmaceutical products.​
​The identification and control of degradation products are particularly important​
​because they may possess pharmacological or toxicological properties different from​
​those of the original drug substance.​

​▪​ ​Sources of Impurities in Medicinal Substances :​

I​ mpurities may arise during raw material procurement, manufacturing, purification,​
​packaging, storage, transportation, and distribution. Identifying their sources is essential for​
​effective impurity control and for ensuring the safety, efficacy, and quality of pharmaceutical​
​products. Regulatory authorities also require impurity profiles to assess their origin,​
​concentration, and toxicological significance.​

​The major sources of impurities in medicinal substances are discussed below.​

​⮚​​Raw Materials :​
​ aw materials used in manufacturing may contain unwanted substances that remain in​
R
​the final product if purification is incomplete. Natural materials often contain minerals,​
​heavy metals, or organic contaminants​​.​

​●​ ​Example​​:​​Sodium chloride prepared from sea water may contain calcium and​
​magnesium salts.​

​⮚​​Manufacturing Process :​
I​ ncomplete chemical reactions, side reactions, or process-related contaminants can​
​introduce impurities.​

​●​ ​Examples :​​Unreacted starting materials, Reaction intermediates, By-products,​

​Catalysts.​

​6​​|​​Page​
 ​⮚​​Reagents and Catalysts :​
​ eagents used during synthesis may remain in trace amounts after completion of the​
R
​reaction.​

​●​ ​Examples:​ ​Hydrochloric acid, Platinum catalys, Nickel catalyst​

​⮚​​Water :​
​ ater used during pharmaceutical manufacturing may introduce dissolved minerals or​
W
​microorganisms if not properly purified. Purified water and Water for Injection (WFI)​
​are therefore used depending on the formulation​

​⮚​​Environmental Contamination :​
​ ust, atmospheric gases, smoke, and airborne particles may contaminate medicinal​
D
​substances during manufacturing.​

​⮚​​Microbial Contamination :​
I​ mproper manufacturing or storage may introduce bacteria, fungi, yeast, or endotoxins​
​into pharmaceutical products.​

​⮚​​Solvents :​
​ rganic solvents are widely used in pharmaceutical synthesis, extraction, purification,​
O
​crystallization, and cleaning. Although most solvents are removed after manufacturing,​
​small amounts may remain as residual solvents. Common solvents include methanol,​
​ethanol, acetone, isopropanol, chloroform, benzene, hexane, toluene, and acetonitrile.​
​Some residual solvents are toxic or carcinogenic; for example, benzene is a known​
​human carcinogen and is permitted only in trace amounts. Therefore, international​
​guidelines classify residual solvents based on their toxicity and specify acceptable​
​limits. Gas chromatography (GC) is the preferred method for their analysis.​

​⮚​​Manufacturing Equipment :​
​ anufacturing equipment can introduce impurities into pharmaceutical products through​
M
​corrosion or mechanical wear. Equipment made of stainless steel, iron, copper, brass, or​
​aluminum may release trace metals such as iron, chromium, nickel, copper, and zinc.​
​These impurities can be minimized by using corrosion-resistant materials, proper​
​equipment maintenance, protective coatings, and regular cleaning procedures.​

​7​​|​​Page​
 ​⮚​​Packaging Materials :​
​ ackaging materials protect pharmaceutical products from environmental​
P
​contamination but may also introduce impurities through chemical interaction or​
​leaching. The major packaging materials include glass containers, plastic containers,​
​rubber closures, metal containers, and aluminum foil.​

​●​ G
​ lass Containers :​​Glass is chemically resistant but may release small amounts​
​of alkali into aqueous preparations, a process known as glass leaching. Leached​
​sodium ions can alter the pH and affect drug stability. Therefore, borosilicate​
​glass is preferred for injectable products.​

​●​ P
​ lastic Containers :​​Plastic containers are lightweight and resistant to breakage​
​but may release additives such as plasticizers, stabilizers, antioxidants, and​
​residual monomers, especially during prolonged storage.​

​●​ R
​ ubber Closures:​​Rubber closures​​used in injectable products may leach sulfur​
​compounds, zinc compounds, and other additives, particularly after repeated​
​sterilization. Compatibility studies are therefore performed before selecting​
​packaging materials.​

​⮚​​Cross-Contamination :​
​ ross-contamination occurs when one pharmaceutical product is contaminated by​
C
​another during manufacturing, usually due to shared equipment or inadequate cleaning.​
​For example, residues of antibiotics may contaminate another product if equipment is​
​not properly cleaned. Even trace amounts of potent drugs can cause allergic reactions​
​or unintended pharmacological effects. Good Manufacturing Practices (GMP)​
​minimize cross-contamination through validated cleaning procedures, dedicated​
​manufacturing areas, and proper production scheduling.​

​⮚​​Human Error :​
​ uman error is a common source of pharmaceutical contamination. It may result from​
H
​incorrect weighing, inadequate equipment cleaning, failure to follow Standard Operating​
​Procedures (SOPs), mislabeling, improper sampling, or poor documentation. Although​
​modern manufacturing is highly automated, trained personnel remain essential.​
​Continuous training, proper documentation, supervision, and quality audits help minimize​
​human errors.​

​➢​​Storage Conditions :​
​ ven after manufacture and purification, medicinal substances may form impurities​
E
​during storage due to physical and chemical degradation. Drug stability is influenced​
​by temperature, humidity, oxygen, carbon dioxide, light, and air pollutants.​
​8​​|​​Page​
 ​⮚​ ​Effect of Temperature :​
​ igh temperatures accelerate degradation reactions such as hydrolysis, oxidation,​
H
​decarboxylation, and polymerization. For example, hydrogen peroxide decomposes​
​into water and oxygen, while sodium bicarbonate decomposes into sodium carbonate,​
​carbon dioxide, and water. Proper temperature control reduces impurity formation.​

​●​ E
​ ffect of Moisture :​​Moisture promotes hydrolysis, particularly in hygroscopic​
​substances. Examples include the hydrolysis of aspirin to salicylic acid and​
​acetic acid, decomposition of certain antibiotics, and premature reaction of​
​effervescent preparations. Proper packaging and moisture-resistant containers​
​help minimize water uptake.​

​●​ E
​ ffect of Oxygen :​​Oxygen causes oxidation, leading to changes in colour,​
​odour, potency, and safety. Examples include the oxidation of ferrous salts,​
​vitamin C (ascorbic acid), and adrenaline. Oxidation is minimized by using​
​antioxidants, nitrogen flushing, airtight containers, and amber-coloured bottles.​

​●​ E
​ ffect of Light:​​Ultraviolet and visible light can cause photodegradation,​
​resulting in loss of potency or formation of toxic degradation products.​
​Light-sensitive drugs include riboflavin, silver nitrate, chlorpromazine, and​
​nifedipine. Such products are stored in amber-coloured containers to protect​
​them from light.​

​⮚​​Impurities Formed During Drug Degradation :​

​ rug degradation is a major source of impurities throughout the shelf life of​
D
​pharmaceutical products. The principal degradation reactions are:​

​●​ H
​ ydrolysis​​:Reaction of drugs​​with water, commonly affecting esters, amides,​
​and lactams.​

​●​ O
​ xidation​​: Loss of electrons or addition of oxygen, promoted by oxygen, heat,​
​light, and metal ions. Drugs containing phenolic or aldehyde groups are​
​particularly susceptible.​

​●​ P
​ hotolysis:​​Light-induced degradation caused by the absorption of light energy​
​and cleavage of chemical bonds.​

​●​ R
​ eduction:​​Degradation of certain drugs in the presence of reducing agents or​
​under anaerobic conditions.​

​9​​|​​Page​
 ​●​ R
​ acemization :​​Conversion of optically active drugs into mixtures of​
​stereoisomers, reducing therapeutic activity.​

​ nowledge of these degradation pathways is essential for developing stable​

K
​formulations, selecting appropriate storage conditions, and establishing​
​stability-indicating analytical methods.​

​▪​ ​Principles of Impurity Analysis :​

I​ mpurity analysis is the systematic identification, characterization, quantification, and control​
​of impurities in pharmaceutical substances. It ensures the safety, efficacy, stability, and​
​quality of medicinal products and is essential during drug development, manufacturing,​
​quality control, and stability studies. Modern analytical techniques detect impurities at ppm​
​or ppb levels.​

​The principles of impurity analysis include the following:​

​●​ I​ dentification​​:​​Determines the chemical identity, structure, molecular weight,​

​functional groups, and source of impurities using techniques such as IR, NMR, MS,​
​and HPLC.​

​●​ S
​ electivity​​:​​The ability of an analytical method to​​distinguish the impurity of interest​
​from APIs, excipients, degradation products, and other components without​
​interference.​

​●​ S
​ pecificity​​:​​The ability to identify and measure a​​specific impurity accurately, even​
​in the presence of chemically similar substances.​

​●​ S
​ ensitivity​​:​​The ability to detect trace levels of​​impurities (ppm or ppb). Highly​
​sensitive techniques include ICP-MS, LC-MS, GC-MS, and HPLC.​

​●​ A
​ ccuracy​​:​​The closeness of the measured value to the true impurity concentration. It​
​is commonly assessed by recovery studies or certified reference materials.​

​●​ R
​ eliability​​:​​The ability of an analytical method to​​produce consistent and dependable​
​results under routine laboratory conditions.​

​●​ R
​ obustness​​:​​The ability of a method to remain unaffected​​by small intentional​
​changes in analytical conditions, such as pH, flow rate, mobile phase composition, or​
​temperature.​

​●​ ​Ruggedness​​:​​The ability of a method to provide consistent​​results when different​

​10​​|​​Page​
 ​analysts, instruments, laboratories, or environmental conditions are involved.​

​●​ L
​ inearity​​:​​The ability of an analytical method to produce results directly​
​proportional to impurity concentration within a specified range.​

​●​ R
​ ange​​:​​The concentration interval over which the method​​provides accurate, precise,​
​and linear results.​

​●​ L
​ imit of Detection (LOD):​​The lowest concentration of an impurity that can be​
​detected but not accurately quantified.​

​●​ M
​ ethod Validation:​​Confirmation that an analytical method is suitable for its​
​intended purpose by evaluating parameters such as accuracy, precision, specificity,​
​sensitivity, robustness, linearity, LOD, and LOQ.​

​●​ R
​ eference Standards:​​Highly purified compounds used​​for the accurate​
​identification and quantification of impurities.​

​●​ ​Sampling​​:​​Collection of representative samples to ensure reliable analytical results.​

​●​ D
​ ocumentation​​:​​Proper recording of sample details,​​analytical methods, instrument​
​settings, observations, calculations, and results to ensure traceability and regulatory​
​compliance.​

​●​ R
​ egulatory Compliance:​​Impurity analysis must comply​​with guidelines issued​
​by ICH, USP, BP, Ph. Eur., and other regulatory authorities, which specify impurity​
​limits, method validation, and documentation requirements.​

​●​ P
​ recision​​:​​Precision is the degree of agreement among​​repeated measurements of the​
​same sample. It indicates the consistency and reproducibility of an analytical method.​
​Precision is evaluated under repeatability, intermediate precision, and reproducibility​
​conditions, ensuring that the method produces consistent results when the analysis is​
​repeated.​

​▪​ ​Qualitative Analysis of Impurities :​

​ ualitative analysis is performed to identify the presence and nature of impurities in​
Q
​pharmaceutical substances. It does not determine the amount of impurity but confirms its​
​identity using suitable chemical or instrumental methods. The commonly employed methods​
​are discussed below:​

​11​​|​​Page​
 ​●​ ​Colour Tests​​:​

​ olour tests are based on the formation of characteristic colours when impurities react​
C
​with specific reagents. For example, iron ions produce a blood-red colour with​
​thiocyanate solution, indicating the presence of iron​

​●​ P
​ recipitation Tests​​: In precipitation tests, impurities react with suitable reagents to​
​form insoluble precipitates. For example, chloride ions produce a white precipitate​
​with silver nitrate, while sulfate ions form a white precipitate with barium chloride.​

​●​ ​Flame Test:​

​ he flame test is used to identify certain metal ions based on the characteristic colour​
T
​they impart to a flame. For example, sodium produces a golden-yellow flame,​
​potassium a violet flame, calcium a brick-red flame, and copper a bluish-green flame.​

​●​ L
​ imit Tests:​​Limit tests determine whether the amount of a specific impurity is​
​within the permissible limit by comparing it with a standard. Common limit tests​
​include those for chloride, sulfate, iron, heavy metals, arsenic, and lead.​

​12​​|​​Page​
 ​●​ ​Chromatographic Methods:​

​ hromatographic techniques separate impurities based on differences in their​

C
​chemical properties, allowing their identification. Common methods include Thin​
​Layer Chromatography (TLC), High-Performance Liquid Chromatography (HPLC),​
​and Gas Chromatography (GC).​

​▪​ ​Quantitative Analysis of Impurities :​

​ uantitative analysis determines the exact amount or concentration of impurities present in​
Q
​pharmaceutical substances. It is essential for ensuring that impurity levels comply with​
​pharmacopeial and regulatory specifications. The commonly used methods are described​
​below :​

​●​ T
​ itrimetric Analysis:​​Titrimetric methods determine impurity concentration by​
​measuring the volume of a standard solution required to complete a chemical reaction.​
​Common types include acid-base, redox, complexometric, and precipitation titrations.​

​●​ G
​ ravimetric Analysis:​​In gravimetric analysis, the impurity is converted into an​
​insoluble compound, which is filtered, dried, and weighed to determine its amount. For​
​example, sulfate is estimated as barium sulfate.​

​●​ I​ nstrumental Analysis:​​Instrumental methods provide highly accurate and​

​sensitive quantitative analysis of impurities.​

​13​​|​​Page​
 ​➔​​High-Performance Liquid Chromatography (HPLC):​

​ he most widely used technique for pharmaceutical impurity profiling due to its​
T
​high sensitivity, accuracy, and precision.​

​➔​​Gas Chromatography (GC):​

​Used for the determination of volatile impurities and residual solvents.​

​14​​|​​Page​
 ​➔​​Atomic Absorption Spectroscopy (AAS):​

​ sed for the quantitative analysis of trace metals such as lead, cadmium, and​
U
​mercury.​

​➔​​Inductively Coupled Plasma–Mass Spectrometry (ICP-MS):​

​A highly sensitive technique for detecting elemental impurities at​

​15​​|​​Page​
 ​parts-per-billion (ppb) levels.​

​➔​​UV-Visible Spectrophotometry:​​Used for the quantitative determination of​

​coloured compounds based on light absorption.​

​➔​​Potentiometric Methods:​​Used to determine impurity concentration by​

​measuring electrode potential during acid-base and precipitation titrations.​

​▪​ ​Tests of Purity:​

​ ests of purity are performed to ensure that medicinal substances comply with pharmacopeial​
T
​standards and are free from harmful impurities. These tests evaluate the physical, chemical,​
​and microbiological quality of pharmaceutical substances to ensure their safety, efficacy, and​
​stability. The commonly used purity tests are described below :​

​●​ A
​ ppearance Test:​​The substance is examined for its​​prescribed colour, texture,​
​clarity, and physical appearance. Any abnormal change may indicate the presence of​
​impurities or degradation.​

​●​ S
​ olubility Test:​​The substance should exhibit the​​specified solubility characteristics​
​in the prescribed solvent. Deviations from the standard may indicate contamination or​
​adulteration.​

​●​ M
​ elting Point Determination:​​Pure solid substances have a sharp and​
​characteristic melting point. The presence of impurities usually lowers the melting point​
​and broadens the melting range.​

​●​ B
​ oiling Point Determination:​​The boiling point is determined for liquid medicinal​
​substances to assess their purity. A deviation from the specified boiling point may​
​indicate the presence of impurities.​

​●​ p
​ H Determination:​​Many pharmaceutical substances require a specified pH range​
​to maintain their stability, efficacy, and compatibility. Changes in pH may indicate​
​contamination or degradation.​

​●​ L
​ oss on Drying:​​This test determines the amount of moisture and volatile substances​
​present in the sample by measuring the weight loss after drying.​

​●​ R
​ esidue on Ignition:​​This test measures the amount of inorganic residue remaining​
​after complete combustion, indicating contamination with non-volatile inorganic​
​materials.​

​16​​|​​Page​
 ​●​ A
​ sh Test:​​The ash test determines the total inorganic impurities present in a medicinal​
​substance after incineration.​

​●​ L
​ imit Test for Chloride:​​This test detects chloride​​impurities by comparing the​
​turbidity produced with silver nitrate against a standard.​

​●​ L
​ imit Test for Sulfate:​​Sulfate impurities are detected by the formation of turbidity​
​with barium chloride, which is compared with a standard solution.​

​●​ L
​ imit Test for Iron:​​Iron contamination is detected using reagents such as​
​thioglycolic acid or thiocyanate, which produce characteristic coloured complexes.​

​●​ L
​ imit Test for Heavy Metals:​​This test determines the presence of toxic metals​
​such as lead, mercury, cadmium, and arsenic, ensuring they remain within permissible​
​limits.​

​●​ R
​ esidual Solvent Analysis:​​Residual organic solvents​​are determined by Gas​
​Chromatography (GC) because of its high sensitivity and specificity.​

​●​ M
​ icrobial Limit Test:​​This test determines whether​​the microbial contamination in​
​pharmaceutical substances is within acceptable pharmacopeial limits, ensuring product​
​safety.​

​▪​ ​Modern Analytical Techniques Used in Impurity Analysis:​

​ odern analytical techniques have significantly improved pharmaceutical impurity analysis​
M
​by providing high sensitivity, specificity, accuracy, and precision. Unlike conventional​
​methods, these techniques can detect and quantify impurities at ppm or ppb levels and are​
​widely accepted for pharmaceutical quality control.​

​The following modern analytical techniques are widely used for impurity analysis :​

​●​ H
​ igh-Performance Liquid Chromatography (HPLC):​​HPLC separates​
​compounds based on their interaction with the stationary and mobile phases. It is widely​
​used for the analysis of organic impurities, degradation products, related substances,​
​and active pharmaceutical ingredients (APIs).​

​●​ G
​ as Chromatography (GC):​​GC is used for the analysis​​of volatile impurities and​
​residual solvents, including methanol, ethanol, acetone, benzene, toluene, and​
​chloroform. It provides excellent sensitivity and separation.​

​●​ A
​ tomic Absorption Spectroscopy (AAS):​ ​AAS determines trace metallic​
​impurities such as lead, cadmium, mercury, copper, iron, and zinc by measuring the​
​17​​|​​Page​
 ​absorption of light by free atoms.​

​●​ I​ nductively Coupled Plasma–Mass Spectrometry (ICP–MS):​​ICP–MS is a​

​highly sensitive technique for the simultaneous determination of elemental impurities at​
​ppb levels and is widely used for regulatory compliance.​

​●​ I​ nfrared Spectroscopy (IR):​​IR spectroscopy identifies compounds by measuring​

​the absorption of infrared radiation. It is used to confirm drug identity and detect​
​structural changes due to degradation.​

​●​ U
​ ltraviolet–Visible Spectrophotometry (UV–Visible):​​UV–Visible​
​spectrophotometry measures light absorption to determine the concentration of​
​pharmaceutical substances. It is commonly used for routine assay and quantitative​
​impurity analysis.​

​●​ N
​ uclear Magnetic Resonance (NMR):​​NMR spectroscopy​​provides detailed​
​information on the molecular structure, functional groups, and stereochemistry of​
​compounds. It is valuable for identifying unknown impurities and degradation products.​

​●​ M
​ ass Spectrometry (MS):​​MS determines the mass-to-charge​​(m/z) ratio of ions​
​for accurate molecular weight determination and impurity identification. It is often​
​combined with LC–MS or GC–MS for structural characterization.​

​▪​ ​Conclusion:​
I​ mpurities are unavoidable in medicinal substances and may be introduced during​
​manufacturing, purification, packaging, storage, transportation, or degradation. Therefore,​
​their identification, characterization, quantification, and control are essential to ensure the​
​safety, efficacy, stability, and quality of pharmaceutical products. Modern analytical​
​techniques such as HPLC, GC, AAS, ICP–MS, NMR, IR spectroscopy, and mass​
​spectrometry enable the accurate detection and quantification of impurities, while​
​international guidelines issued by ICH and official pharmacopoeias (USP, BP, IP, and Ph.​
​Eur.) provide standardized limits and analytical procedures. Thus, impurity analysis is a vital​
​component of pharmaceutical chemistry and quality assurance, ensuring that medicinal​
​products remain safe, effective, and of consistently high quality.​

​▪​ ​References:​
1​ . S. Z. Haider. Modern Inorganic Chemistry.​
​2. J. D. Lee. Inorganic Chemistry.​
​3. Rogers. Textbook of Inorganic Pharmaceutical Chemistry.​
​4. Block and Willson. Inorganic, Medicinal and Pharmaceutical Chemistry.​
​18​​|​​Page​
 5​ . Discher. Modern Inorganic Pharmaceutical Chemistry.​
​6. United States Pharmacopeia (USP).​
​7. British Pharmacopoeia (BP).​
​8. International Council for Harmonisation (ICH) Guidelines on Impurities.​
​9. Relevant peer-reviewed articles from Google Scholar and ScienceDirect.​

​19​​|​​Page​